| BRITISH COLUMBIA CANCER AGENCY BRANCH Patent applications |
| Patent application number | Title | Published |
|---|
| 20120123184 | SYSTEMS AND METHODS FOR OPTIMIZATION OF ON-LINE ADAPTIVE RADIATION THERAPY - Radiation treatment methods comprise: obtaining initial image data of a region of interest; initially optimizing one or more radiation delivery variables of a radiation treatment plan based on the initial image data; and dividing the plan into one or more fractional treatments. Each fractional treatment comprises: delivering an initial portion of a fraction based on the one or more initially optimized radiation delivery variables; obtaining fractional image data pertaining to the region of interest; fractionally optimizing the one or more radiation delivery variables based at least in part on the fractional image data; and delivering a subsequent portion of the fraction based on the one or more fractionally optimized radiation delivery variables. At least part of delivering the initial portion of the fraction overlaps temporally with at least one of: obtaining the fractional image data and fractionally optimizing the one or more radiation delivery variables. | 05-17-2012 |
| 20120089030 | SYSTEM AND METHOD FOR CHARACTERIZATION OF ORAL, SYSTEMIC AND MUCOSAL TISSUE UTILIZING RAMAN SPECTROSCOPY - A method and system for characterizing tissue includes a probe connected to a red LASER source and a Raman spectroscope. The probe includes at least excitation fiber and one or more emission fibers that connect the probe with the LASER source and the Raman spectroscope. The excitation fiber is connected to the red LASER source and terminates in the first end of the probe adjacent the tip of the probe. The emission fibers are connected to the Raman spectroscope and terminate in the first end of the probe adjacent the tip of the probe. In one embodiment, the excitation fiber extends through the central portion of the probe and one or more emission fibers are arranged around the excitation fiber. The tip of the probe is intended to come in contact with the tissue to be examined. The tip includes a central opening to allow red LASER radiation to project out of the end of the red excitation fiber on to the tissue and to permit Raman spectra to enter the emission fiber(s) and travel to the Raman spectroscope. The tip is constructed to have a predefined focal length to position the first end of the probe a predefined distance from the surface of the tissue being examined. The tip can be removable and tips having different focal lengths can be used to accommodate different types of tissues and examinations. A detector can convert the Raman spectra into signals and data for analysis by a computer system. The Raman spectra for tissue in a predefined location can be profiled such that the system can distinguish between healthy and diseased tissue. | 04-12-2012 |
| 20120061590 | SELECTIVE EXCITATION LIGHT FLUORESCENCE IMAGING METHODS AND APPARATUS - Imaging methods and apparatus may be applied to image tissues as well as other areas. A computer-controlled color-selectable light source is controlled to emit light having a desired spectral profile and to illuminate an area. An imaging detector images the illuminated area. The spectral profile may be selected to yield images in which contrast between features of interest and other features is enhanced. The images may be combined into a composite image. In some embodiments the spectral profile is based on a principal components analysis such that the images each correspond to one principal component. | 03-15-2012 |
| 20120059346 | VIAL HANDLING AND INJECTION SAFETY SYSTEMS AND CONNECTORS - Systems and devices are provided to facilitate safe handling and injection of medicaments contained in vials. A vial handling system has at least one vial gripping member to hold a vial, and a filler pin movable relative to the vial gripping member for piercing a membrane seal on the vial. At least one window is provided in the vial handling system to permit access to remove a cap on the vial, while preventing needle access to the membrane seal through the window. In some embodiments, the vial contents are removed through a male end connector portion of a unique connector pair. A female end connector portion has a female socket with an inner fluid tube in fluid communication with a body of a syringe, while the male end connector portion has an engaging end dimensioned to fit within the female socket and securely overlap the inner fluid tube. | 03-08-2012 |
| 20120027793 | COMPOSITIONS COMPRISING CHLAMYDIA ANTIGENS - There is provided a composition for inducing an immune response to a | 02-02-2012 |
| 20110244024 | MICRORNA COMPOSITIONS AND METHODS FOR THE TREATMENT OF MYELOGENOUS LEUKEMIA - The invention provides methods, uses, kits and compositions comprising a therapeutically effective amount of the microRNA miR-223 for treating myelogenous leukemia in a subject in need of such treatment. The invention further comprises methods encompassing the use of miR-223 for promoting the differentiation of a leukemia stem cell that is resistant to a differentiating agent, and a method of screening for candidate compounds capable of treating a myeloid leukemia by comparison of the therapeutic activity of the candidate compound with the therapeutic activity of miR-233. | 10-06-2011 |
| 20110224313 | COMPOSITIONS AND METHODS FOR CLASSIFYING LUNG CANCER AND PROGNOSING LUNG CANCER SURVIVAL - The application provides methods of prognosing, diagnosing, screening and classifying lung cancer patients into poor survival groups or good survival groups. A number of altered genomic regions have been identified that distinguish subtype of lung adenocarcinoma (ADC), specifically between bronchioloalveolar carcinoma (BAC) and invasive ADC with BAC features (AWBF), and genes and biomarkers whose expression are altered in individuals with pulmonary ADC according to different survival outcomes. The amplification and/or deletion of these genomic regions, and/or the biomarker expression profiles can be used to classify patients with ADC into a BAC group with excellent survival outcome, or an invasive ADC with BAC features group with higher risk of developing metastatic recurrence and poorer survival outcome. The application also includes kits for use in the methods of the application. | 09-15-2011 |
| 20110195070 | DETECTION OF GRANULOSA-CELL TUMORS - A method of detecting a granulosa-cell tumor is described herein. The method involves detecting a mutation in a sample derived from a subject, indicative of substitution of tryptophan in place of cysteine at amino acid position 134 of FOXL2 protein. The mutation may be detected as a DNA mutation 402C>G in the FOXL2 gene. Methods for screening for a granulosa-cell tumor from a blood-based assay are provided, as well as methods for making a determination that an ovarian tumor is not a granulosa-cell tumor. Kits for granulosa-cell tumors are described, and a method of treating a granulosa-cell tumor are also described. | 08-11-2011 |
| 20110195064 | SURVIVAL PREDICTOR FOR DIFFUSE LARGE B CELL LYMPHOMA - The invention provides methods and materials related to a gene expression-based survival predictor for diffuse large B cell lymphoma (DLBCL) patients. | 08-11-2011 |
| 20110009369 | ANTI-INFLUENZA COMPOUNDS - The present invention provides pyrimidinyl compounds of formula (I) and pharmaceutically acceptable salts thereof. These compounds may be used for the inhibition of influenza. In particular, the compounds of the invention may be used for the treatment or prophylaxis of influenza A, most particularly H1N1 or H5N1 influenza. The compounds of the invention can also be used for the treatment or prophylaxis of a disease caused by | 01-13-2011 |
| 20100317533 | BIOMARKERS OF CANCER METASTASIS - There is provided a panel of biomarkers of tumour metastasis comprising any two of carbonic anhydrase-9 (CAIX), vascular endothelial growth factor C (VEGF-C), ephrin A5 (EFNA5), eph receptor B2 (EPHB2), transforming growth factor beta 3 (TGF-β3), pyruvate dehydrogenase kinase isoenzyme-3 (PDK3), carbonic anhydrase-12 (CAXII), keratin 14 (KRT14), hypoxia inducible factor 1 alpha subunit (HIF-1α), or tenascin C (TNC). CAIX, VEGF-C, EFNA5, EPHB2, TGF-β3 or PDK3 may be indicators of moderate metastatic potential, while CAXII, KRT14, HIF-1α, or TNC may be indicators of high metastatic potential. There is also provided a method of determining risk of tumour metastasis using the aforementioned biomarkers is also provided. The biomarkers may be used in diagnosis, prognosis, treatment selection, or to test putative therapeutics. The biomarkers may be used to assess malignancies or cancers having hypoxic regions, such as breast cancer. | 12-16-2010 |
| 20100290692 | SYSTEMS AND METHODS FOR AUTOMATED CHARACTERIZATION OF GENETIC HETEROGENEITY IN TISSUE SAMPLES - Systems and methods for the quantitative automated analysis of pathology samples identify groups of spatially-associated similar cells. Cells may be identified as belonging to a group on the basis of spatial location and biomarkers. In some embodiments the biomarkers are multicolour fluorescence in situ hybridization (FISH) signals. Characteristics of the cells in a group may be combined to provide quantitative FISH results that may compensate for variations and artefacts such as thin sectioning that can result in the loss of information due to damage. In heterogeneous tissue samples, grouping cells can permit quantitative results regarding pathological cells to be extracted despite the presences of infiltrating non pathological cells. | 11-18-2010 |
| 20100248290 | METHODS FOR DETECTING LUNG CANCER AND MONITORING TREATMENT RESPONSE - A method is described for detecting lung cancer comprising detecting an elevated level of a CTAP III-related biomarker in a biological sample from a subject at risk for developing lung cancer. Further, a method is described for predicting risk of developing lung cancer in a subject comprising detecting an elevated level of a CTAP III-related biomarker in a biological sample from a subject. Additionally, a method of monitoring the success of lung cancer treatment with curative intent is described comprising detecting levels of a CTAP III-related biomarker in a biological sample from a subject undergoing treatment for lung cancer for comparison with the a previous level obtained from the subject. Multivariate analysis may be incorporated into these methods, evaluating such clinical, or demographic risk factors as age, sex, smoking history, smoking status, smoking family history, education level, COPD, socio-economic status, body mass index and lung function. Kits for conducting such methods are described. | 09-30-2010 |
| 20090035318 | METHOD AND COMPOSITION FOR INCREASING THE ENGRAFTMENT EFFICIENCY OF STEM CELLS - A method is described for increasing the engraftment efficiency of S/G | 02-05-2009 |
| 20090011456 | Methods for the Diagnosis and Prognosis of Graft Versus Host Disease By Measurement of Peripheral Cd3+Cd4+Cd8Beta+ Cells - Acute graft versus host disease (GvHD) is one of the most significant clinical problems in allogeneic blood and marrow transplantation. Currently, there is no unequivocal diagnostic test for GvHD until the disease is well developed and can be recognized histologically. The invention provides a blood based test for diagnosis and/or prognosis of GvHD, allowing assessment of risk for developing GvHD prior to appearance of clinical symptoms. Using flow cytometry, peripheral blood mononuclear cells are assessed for an increase in proportion and fluctuation of CD3 | 01-08-2009 |
